1. Andriankaja OM, Barros SP, Moss K, Panagakos FS, DeVizio W, Beck J, et al. Levels of serum interleukin (IL)-6 and gingival crevicular fluid of IL-1beta and prostaglandin E(2) among non-smoking subjects with gingivitis and type 2 diabetes. J Periodontol 2009; 80: 307-316.
2. Sathe N, Beech P, Croft L, Suphioglu C, Kapat A, Athan E. Pseudomonas aeruginosa: Infections and novel approaches to treatment “Knowing the enemy” the threat of Pseudomonas aeruginosa and exploring novel approaches to treatment. Infect Med (Beijing) 2023; 2: 178-194.‏
3. Arularasi Aberna R, Prabakaran K. Evaluation for the association of virulence determinants among E. faecalis with its clinical outcome. Int J Biol Med Res 2011; 2: 523-527.
4. Atabek A (2006). Investigating bacterial outer membrane polymers and bacterial interactions with organic molecules using atomic force microscopy. Worcester Polytechnic Institute.
5. Bennett PM. Plasmid encoded antibiotic resistance: acquisition and transfer of antibiotic resistance genes in bacteria. Br J Pharmacol 2008; 153 Suppl 1(Suppl 1): S347-S357.
6. Azucena E, Mobashery S. Aminoglycoside-modifying enzymes: mechanisms of catalytic processes and inhibition. Drug Resist Updat 2001; 4: 106-117.
7. Bahgat MM, Elbialy AA, Zaky MMM, Toubar SME. Prevalence of antibiotic resistant aerobic bacteria isolated from Surgical wounds of inpatients at Zagazig university hospitals, Egypt. Int J Curr Microbiol Appl Sci 2015; 4: 460-472.
8. Baker RJ, Senior H, Clemenger M, Brown EA. Empirical aminoglycosides for peritonitis do not affect residual renal function. Am J Kidney Dis 2003; 41: 670-675.
9. Balaban N, Cirioni O, Giacometti A, Ghiselli R, Braunstein JB, Silvestri C, et al. Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP. Antimicrob Agents Chemother 2007; 51: 2226-2229.
10. Gajdács M, Baráth Z, Kárpáti K, Szabó D, Usai D, Zanetti S, et al. No correlation between biofilm formation, virulence factors, and antibiotic resistance in Pseudomonas aeruginosa: results from a laboratory-based in vitro study. Antibiotics (Basel) 2021; 10: 1134.‏
11. Baqai R, Aziz M, Rasool G. Urinary tract infection in diabetic patients and biofilm formation of uropathogens. Infect Dis J Pak 2008; 17: 7-9.
12. Barnett MJ, Fisher RF, Jones T, Komp C, Abola AP, Barloy-Hubler F, et al. Nucleotide sequence and predicted functions of the entire Sinorhizobium meliloti pSymA megaplasmid. Proc Natl Acad Sci U S A 2001; 98: 9883-9888.
13. Baron EJ. Rapid identification of bacteria and yeast: summary of a national committee for clinical laboratory standards proposed guideline. Clin Infect Dis 2001; 33: 220-225.
14. Barrett AJ, Woessner JF, Rowling ND (2004). Handbook of proteolytic enzymes, Volume 1. 2th ed. Academic press. https://shop.elsevier.com/books/handbook-of-proteolytic-enzymes-volume-1/barrett/978-0-12-079611-3
15. Baucheron S, Chaslus-Dancla E, Cloeckaert A. Role of TolC and parC mutation in high-level fluoroquinolone resistance in Salmonella enterica serotype Typhimurium DT204. J Antimicrob Chemother 2004; 53: 657-659.
16. Saeli N, Jafari-Ramedani S, Ramazanzadeh R, Nazari M, Sahebkar A, Khademi F. Prevalence and mechanisms of aminoglycoside resistance among drug-resistant Pseudomonas aeruginosa clinical isolates in Iran. BMC Infect Dis 2024; 24: 680.
17. Caiazza NC, O'Toole GA. Alpha-toxin is required for biofilm formation by Staphylococcus aureus. J Bacteriol 2003; 185: 3214-3217.
18. Tendolkar PM, Baghdayan AS, Shankar N. The N-Terminal domain of enterococcal surface protein, Esp, is sufficient for Esp-Mediated Biofilm Enhancement in Enterococcus faecalis. J Bacteriol 2005; 187:6213-6222.